Merck & Co Could Be Plotting $30bn Bid For Seagen
Regulatory Concerns Remain
A buyout of Seagen would boost Merck & Co’s goal of becoming the dominant player in oncology by 2025, but the deal is said to be far from done.
You may also be interested in...
Seagen was being pursued by another prospective big pharma buyer when it engaged Pfizer in merger negotiations, but both bidders walked away in late summer 2022; Pfizer returned in January.
Merck & Co. CEO Rob Davis said the company is already factoring policy changes from the Inflation Reduction Act into its business development decisions.
Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.